156 related articles for article (PubMed ID: 8144932)
21. Melphalan-induced appearance of potent antitumor immune reactivity in tumor bearer lymphocytes co-expressing the Lyt 2 and the L3T4 antigens.
Takesue BY; Bartik MM; Mokyr MB
Int J Immunopharmacol; 1987; 9(6):705-17. PubMed ID: 2891627
[TBL] [Abstract][Full Text] [Related]
22. Neurotransmitter suppression of the in vitro generation of a cytotoxic T lymphocyte response against the syngeneic MOPC-315 plasmacytoma.
Cook-Mills JM; Mokyr MB; Cohen RL; Perlman RL; Chambers DA
Cancer Immunol Immunother; 1995 Feb; 40(2):79-87. PubMed ID: 7882386
[TBL] [Abstract][Full Text] [Related]
23. Classification of anticancer chemotherapeutic drugs according to their immunopotentiating activity.
Ben-Efraim S; Shoval S; Gal T; Ophir R
Anticancer Res; 1986; 6(4):801-5. PubMed ID: 2944475
[TBL] [Abstract][Full Text] [Related]
24. Enhanced expansion of the thymic CD8+ cell subset as a potential mechanism for the generation of enhanced antitumor cytotoxicity by thymocytes from low-dose melphalan-treated MOPC-315 tumor bearers.
Bartik MM; Baumgartel-Scofield BA; Mokyr MB
Cancer Immunol Immunother; 1991; 34(2):79-89. PubMed ID: 1760820
[TBL] [Abstract][Full Text] [Related]
25. Cyclophosphamide-induced appearance of immunopotentiating T-cells in the spleens of mice bearing a large MOPC-315 tumor.
Ye QW; Mokyr MB
Cancer Res; 1984 Sep; 44(9):3873-9. PubMed ID: 6611201
[TBL] [Abstract][Full Text] [Related]
26. Specificity of the generation and expression of enhanced anti-plasmacytoma immunity by spleen cells from melphalan-treated MOPC-315 tumor bearers.
Mokyr MB; Barker E
Cancer Immunol Immunother; 1986; 23(1):11-9. PubMed ID: 3490305
[TBL] [Abstract][Full Text] [Related]
27. Advantages of adoptive chemoimmunotherapy with polyethylene glycol-cultured, antigen-activated, tumor-infiltrated spleen cells for the complete eradication of lethal MOPC-315 plasmacytomas.
Laude M; Siessmann KL; Mokyr MB; Dray S
Cancer Res; 1991 Sep; 51(17):4516-22. PubMed ID: 1873795
[TBL] [Abstract][Full Text] [Related]
28. Augmentation of antitumor immunity with bacterial superantigen, staphylococcal enterotoxin B-bound tumor cells.
Shimizu M; Yamamoto A; Nakano H; Matsuzawa A
Cancer Res; 1996 Aug; 56(16):3731-6. PubMed ID: 8706016
[TBL] [Abstract][Full Text] [Related]
29. Some advantages of curing mice bearing a large subcutaneous MOPC-315 tumor with a low dose rather than a high dose of cyclophosphamide.
Mokyr MB; Dray S
Cancer Res; 1983 Jul; 43(7):3112-9. PubMed ID: 6850619
[TBL] [Abstract][Full Text] [Related]
30. Some characteristics of the in vivo antitumor immunity exhibited by mice cured of a large MOPC-315 tumor by a low dose of melphalan.
Barker E; Mokyr MB
Cancer Immunol Immunother; 1987; 25(3):215-24. PubMed ID: 3677124
[TBL] [Abstract][Full Text] [Related]
31. Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors.
Hengst JC; Mokyr MB; Dray S
Cancer Res; 1981 Jun; 41(6):2163-7. PubMed ID: 7016310
[TBL] [Abstract][Full Text] [Related]
32. Low-dose-melphalan-induced up-regulation of type-1 cytokine expression in the s.c. tumor nodule of MOPC-315 tumor bearers and the role of interferon gamma in the therapeutic outcome.
Gorelik L; Mokyr MB
Cancer Immunol Immunother; 1995 Dec; 41(6):363-74. PubMed ID: 8635194
[TBL] [Abstract][Full Text] [Related]
33. Eradication of a large MOPC-315 tumor in athymic nude mice by chemoimmunotherapy with Lyt2+ splenic T cells from melphalan-treated BALB/c mice bearing a large MOPC-315 tumor.
Weiskirch LM; Barker E; Mokyr MB
Cancer Immunol Immunother; 1990; 31(3):129-38. PubMed ID: 2337902
[TBL] [Abstract][Full Text] [Related]
34. Role of CD8 in staphylococcal enterotoxin B-mediated lysis by cytotoxic T lymphocytes.
Hoo WS; Kranz DM
J Immunol; 1993 May; 150(10):4331-7. PubMed ID: 8482838
[TBL] [Abstract][Full Text] [Related]
35. Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells.
Shu S; Krinock RA; Matsumura T; Sussman JJ; Fox BA; Chang AE; Terman DS
J Immunol; 1994 Feb; 152(3):1277-88. PubMed ID: 8301131
[TBL] [Abstract][Full Text] [Related]
36. Characterization of the exogenous interleukin-2 requirements for the generation of enhanced antitumor cytotoxicity by thymocytes from low-dose melphalan-treated MOPC-315 tumor bearers.
Rubin M; Mokyr MB
Cancer Immunol Immunother; 1993; 36(1):37-44. PubMed ID: 8422666
[TBL] [Abstract][Full Text] [Related]
37. Presence of an enlarged pool of MOPC-315-specific cytotoxic T lymphocyte precursors in the thymuses of mice that eradicated a large MOPC-315 tumor as a consequence of low-dose melphalan therapy.
Bartik MM; Ahn MC; Baumgartel BA; Hendricks RL; Mokyr MB
Cancer Immunol Immunother; 1990; 32(3):143-53. PubMed ID: 2289208
[TBL] [Abstract][Full Text] [Related]
38. Ability of cyclophosphamide in the absence of cross-linking activity to exert the immunomodulatory effect required for the cure of mice bearing a large MOPC-315 tumor.
Mokyr MB; Brundrett RB; Colvin M; Dray S
Cancer Res; 1986 Jul; 46(7):3313-20. PubMed ID: 3486709
[TBL] [Abstract][Full Text] [Related]
39. Induction of tumor-specific antitumor immunity after chemotherapy with cisplatin in mice bearing MOPC-104E plasmacytoma by modulation of MHC expression on tumor surface.
Nio Y; Hirahara N; Minari Y; Iguchi C; Yamasawa K; Toga T; Tamura K
Anticancer Res; 2000; 20(5A):3293-9. PubMed ID: 11062756
[TBL] [Abstract][Full Text] [Related]
40. Enhancement of the effectiveness of Lyt-2+ T-cells for adoptive chemoimmunotherapy by short-term exposure of tumor-bearer spleen cells to polyethylene glycol and/or melphalan.
Wise JA; Mokyr MB; Dray S
Cancer Res; 1989 Jul; 49(13):3613-9. PubMed ID: 2567207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]